Yahoo Finance's Julia La Roche sits down with executive chairman and former CEO of Starbucks Howard Schultz
|Mr. Jack A. Khattar||Founder, Chief Exec. Officer, Pres, Sec. and Director||1.13M||N/A||56|
|Mr. Gregory S. Patrick M.E., M.B.A.||Chief Financial Officer and VP||504.75k||N/A||66|
|Dr. Padmanabh P. Bhatt Ph.D.||Chief Scientific Officer and Sr. VP of Intellectual Property||502.75k||N/A||60|
|Mr. Victor L. Vaughn||Sr. VP of Sales and Marketing||517.16k||N/A||59|
|Dr. Stefan K. F. Schwabe M.D., Ph.D.||Chief Medical Officer and Exec. VP of R&D||566.66k||N/A||65|
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The companys product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
Supernus Pharmaceuticals, Inc.’s ISS Governance QualityScore as of September 1, 2017 is 10. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 8; Compensation: 8.